Last reviewed · How we verify
Tramadol APAP
At a glance
| Generic name | Tramadol APAP |
|---|---|
| Also known as | Ultracet |
| Sponsor | Par Pharmaceutical, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA (NA)
- Analgesic Efficacy and Obstetric Effects of Tramadol, Paracetamol and Placebo in Active Labor (PHASE4)
- NonNarcotic Pain Control in Percutaneous Needle Tenotomy of Elbow (PHASE4)
- Opioid-Free Pain Protocol After Shoulder Arthroplasty (PHASE4)
- Intravenous Paracetamol Versus Intramuscular Tramadol in Shortening the Duration of Labour. (NA)
- Efficacy of Intercostal CryoAnalgesia in Robotic Lung Resection (PHASE4)
- Adding Dexmedetomidine or Tramadol to Paracetamol- An Effort to Attenuate Catheter Related Bladder Discomfort (PHASE3)
- Effectiveness of AI-Guided Exercise and Pain Neuroscience Education for Fibromyalgia (FIBROIA) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tramadol APAP CI brief — competitive landscape report
- Tramadol APAP updates RSS · CI watch RSS
- Par Pharmaceutical, Inc. portfolio CI